| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Dianthus Therapeutics, Inc. (DNTH) has 5 insiders with recent SEC Form 4 filings, including 1 buy and 0 sells. DNTH is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 89.7K | $7.40M | - | |
| Other | 16.2K | $1.33M | - | |
| VP | 8.0K | $659.8K | -26,530 | |
| Dir | 0 | - | - | |
| CEO | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 25, 2018 | Scadden David75 | Director | Buy | 6,600 | $15.00 | $99,000.00 | +3.0% |